Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.44 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.38 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5137880 | 0.94 | C5AR1 (0.45) | LTA4HC5AR1LTB4R2PIN1TSHR | |
| SCHEMBL650270 | 0.93 | C5AR1 (0.43) | LTA4HC5AR1LTB4R2TSHRAGTR1 | |
| SCHEMBL5136627 | 0.93 | KDM4E (0.41) | LTA4HC5AR1LTB4R2PIN1LPAR1 | |
| SCHEMBL4766957 | 0.92 | C5AR1 (0.42) | LTA4HC5AR1TSHRAGTR1AGTR2 | |
| SCHEMBL648502 | 0.92 | LTA4H (0.42) | LTA4HC5AR1LTB4R2AGTR1AGTR2 | |
| SCHEMBL5135677 | 0.92 | C5AR1 (0.42) | C5AR1LTB4R2HDAC1 | |
| SCHEMBL5135950 | 0.91 | LPAR1 (0.42) | C5AR1AGTR1HDAC1LPAR1LPAR5 | |
| SCHEMBL5137860 | 0.91 | C5AR1 (0.41) | C5AR1TSHRAGTR1AGTR2HDAC1 | |
| SCHEMBL5137489 | 0.90 | C5AR1 (0.48) | C5AR1TSHR | |
| SCHEMBL649161 | 0.90 | C5AR1 (0.47) | C5AR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |